| BAY 43-9006 inhibition of oncogenic RET mutants F Carlomagno, S Anaganti, T Guida, G Salvatore, G Troncone, ... Journal of the National Cancer Institute 98 (5), 326-334, 2006 | 578 | 2006 |
| Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors F Carlomagno, T Guida, S Anaganti, G Vecchio, A Fusco, AJ Ryan, ... Oncogene 23 (36), 6056-6063, 2004 | 286 | 2004 |
| Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor β gatekeeper mutants T Guida, S Anaganti, L Provitera, R Gedrich, E Sullivan, SM Wilhelm, ... Clinical cancer research 13 (11), 3363-3369, 2007 | 87 | 2007 |
| Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies D Bossi, F Carlomagno, I Pallavicini, G Pruneri, M Trubia, PR Raviele, ... Molecular oncology 8 (2), 221-231, 2014 | 60 | 2014 |
| p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines L Fernandez‐Cuesta, S Anaganti, P Hainaut, M Olivier International Journal of Cancer 128 (8), 1813-1821, 2011 | 51 | 2011 |
| Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines L Fernández-Cuesta, S Anaganti, P Hainaut, M Olivier Breast cancer research and treatment 125, 35-42, 2011 | 47 | 2011 |
| Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474 F Carlomagno, T Guida, S Anaganti, L Provitera, S Kjaer, NQ McDonald, ... Endocrine-related cancer 16 (1), 233, 2009 | 42 | 2009 |
| p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines S Anaganti, L Fernández-Cuesta, A Langerød, P Hainaut, M Olivier Cancer letters 300 (2), 215-224, 2011 | 29 | 2011 |
| Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. L D'Aloiso, F Carlomagno, M Bisceglia, S Anaganti, E Ferretti, A Verrienti, ... The Journal of Clinical Endocrinology and Metabolism 91 (3), 754-759, 2005 | 24 | 2005 |
| In Vivo and in Vitro Characterization of a Novel Germline RET Mutation Associated with Low-Penetrant Nonaggressive Familial Medullary Thyroid Carcinoma L D’Aloiso, F Carlomagno, M Bisceglia, S Anaganti, E Ferretti, A Verrienti, ... The Journal of Clinical Endocrinology & Metabolism 91 (3), 754-759, 2006 | 9 | 2006 |
| Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines M Olivier, L Fernández-Cuesta, S Anaganti, P Hainaut Springer US, 2011 | 1 | 2011 |
| Neurotensin receptor antagonist, SR48692, sensitizes prostate cancer cells to radiation in vitro and in vivo EV Casarez, JO DaSilva, NCK Valerie, S Anaganti, ME Dunlap-Brown, ... Cancer Research 71 (8_Supplement), 2505-2505, 2011 | | 2011 |
| Doctorate Program in Molecular Oncology and Endocrinology S Anaganti | | |
